Becondogrel

2026年4月，由成都施贝康生物医药科技有限公司（简称 “施贝康”）自主研发的全新一代抗血小板药物 sbk002（吡康格雷，Becondogrel）临床研究成果，在第 75 届美国心脏病学会（ACC.26）科学年会上完成展示与学术交流。相关研究摘要《PK/PD CHARACTERISTICS OF BECONDOGREL IN HEALTHY SUBJECTS WITH DIFFERENT CYP2C19 METABOLIC GENOTYPES》，已同步发表于《美国心脏病学会杂志》（Journal of the American College of Cardiology, JACC）。 ACC 年会：全球心血管领域学术标杆 美国心脏病学会（ACC）科学年会是国际公认的心血管病学领域顶级学术会议，第 75 届 ACC 年会于 2026 年 3 月 28 日 - 30 日举办，以 “为所有人开启心血管诊疗变革” 为主题，汇聚全球 140 个国家的 23000 余名心血管领域专家、研究者及产业代表，吡康格雷研究成果成功入选并完成现场展示与学术交流。 ACC.26现场展示与交流 JACC 期刊：心血管领域国际顶刊 JACC 作为美国心脏病学会官方旗舰期刊，位列全球心血管学科期刊 Q1 分区，2024 年最新影响因子为 22.3，是全球心血管领域公认的顶级期刊。该期刊专注刊发心血管领域高质量、高创新性的原创临床与转化研究成果，其内容是指导全球心血管临床诊疗、科研创新及指南制定的核心文献来源。吡康格雷研究成果已发表于JACC 期刊2026年4月7日刊（Volume 87, Number 13_Supplement）。 目前，施贝康正在有序推进吡康格雷的临床应用与全球化布局，为心血管疾病治疗提供新的选择。 JACC期刊《PK/PD CHARACTERISTICS OF BECONDOGREL IN HEALTHY SUBJECTS WITH DIFFERENT CYP2C19 METABOLIC GENOTYPES》 https://www.jacc.org/doi/10.1016/j.jacc.2026.02.422 成都施贝康生物医药科技有限公司，成立于2015年，是一家立足中国，面向全球，专注于新药差异化创新的研发性企业。施贝康秉承“施予众生、倍佑安康”的使命，坚持“以‘人’为本，革新为主，创新至上”的价值观。以临床需求为导向，坚持创新驱动发展，重点聚焦心脑血管、呼吸系统等疾病治疗领域，致力于成为全球一流的新药差异化创新的领导者，研发更好的新药，施予众生，加倍呵护人类健康。 详情请访问公司网站： https://www.sbkswyy.cn/ Shibeikang's Clinical Study Results of Becondogrel Presented at ACC 2026 and Published in JACC, a Leading International Cardiovascular Journal In April 2026, the clinical study results of sbk002 (Becondogrel), a next-generation antiplatelet agent independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as "Shibeikang"), were presented and served as a basis for academic exchange at the 75th Annual Scientific Session of the American College of Cardiology (ACC.26). The study abstract, titled "PK/PD CHARACTERISTICS OF BECONDOGREL IN HEALTHY SUBJECTS WITH DIFFERENT CYP2C19 METABOLIC GENOTYPES,” was simultaneously published in the Journal of the American College of Cardiology (JACC). ACC Annual Session: A Global Benchmark in Cardiovascular Academia The ACC Annual Scientific Session is internationally recognized as a premier academic conference in in the field of cardiovascular disease. The 75th ACC Annual Session was held from March 28 to 30, 2026, under the theme "Transforming Cardiovascular Care for All." The event brought together more than 23,000 cardiovascular experts, researchers, and industry representatives from over 140 countries worldwide. The becondogrel study results were successfully selected for presentation and academic exchange at the conference. JACC: A Leading International Journal in the Cardiovascular Field JACC, the flagship journal of the American College of Cardiology, is ranked in Q1 among cardiovascular journals worldwide. With an impact factor of 22.3 (2024), JACC is widely recognized as a leading journal in the global cardiovascular field. The journal focuses on publishing high-quality, highly innovative original clinical and translational research findings, serving as a core source of literature guiding global clinical cardiovascular practice, research innovation, and guideline development. The study results of becondogrel were published in the April 7, 2026 issue of JACC (Volume 87, Number 13_Supplement). Currently, Shibeikang is steadily advancing the clinical application and global strategic development of becondogrel, aiming to provide a new treatment option for patients with cardiovascular disease. Founded in 2015,Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment. For further details, please visit the official SBK website： https://www.sbkswyy.cn/